News and features

Read the latest news and features about our world-leading research, discoveries, fundraising and philanthropy. If you want to keep updated on our news, you can follow us on social media or sign up for our Search newsletter.

If you’re a journalist and want to find out more, you can contact our media relations team.

ICR Logo
Trial Helps Bring New Prostate Cancer Drug to Market

01/10/10

A drug that the ICR and The Royal Marsden helped develop extends the life of men with advanced prostate cancer.
ICR Logo
The Institute of Cancer Research names Professor Alan Ashworth FRS as new CEO

17/09/10

Europe’s leading cancer research centre, The Institute of Cancer Research (ICR), has named eminent scientist Professor Alan Ashworth as its new Chief Executive. Professor Ashworth will take up the appointment in January.
ICR Logo
Scientists Unravel Genetic Risk of Bowel Cancer

16/09/10

An international study led by scientists at the ICR has shown how a single variant in a person’s DNA can promote bowel cancer development.
ICR Logo
First Major Study Supports Screening in Men at Higher Genetic Risk of Prostate Cancer

10/09/10

Men at higher risk of prostate cancer due to genetic changes may benefit from regular screening, according to preliminary results from the first multinational study of patients.
ICR Logo
Scientists Make Major Discovery in Finding Origins of Aggressive Breast Cancer

02/09/10

Scientists have made a major step towards answering one of the fundamental questions in breast cancer research – where the disease originates. This raises hope of new targeted treatments for women with breast cancer in the future.
ICR Logo
Research Opens Door to New Drugs That Will Counter Tamoxifen Resistance

30/08/10

A discovery by Professor Clare Isacke and her team at the Breakthrough Breast Cancer Research Centre at The Institute of Cancer Research (ICR) could open the door to new treatments for those who have developed a resistance to tamoxifen
ICR Logo
ICR and Horizon Discovery to Collaborate on Genome-wide Synthetic-lethality Screens

27/08/10

The ICR and Horizon Discovery (Horizon) are forming a collaboration aimed at rapidly screening the human genome for novel drug targets that selectively kill cancer cells.
ICR Logo
New Test Could Reveal Chemotherapy Benefit in 24 Hours

27/08/10

Scientists have developed a new test to indicate whether the most commonly-used chemotherapy drug will benefit a breast cancer patient within 24 hours of taking it. The test also identifies patients who may benefit from PARP inhibitors, a promising new class of cancer treatment.
ICR Logo
Herpes Virus Treats Head and Neck Cancer Patients

30/07/10

A genetically engineered cold sore virus has been used to treat head and neck cancer patients in a Phase I/II clinical trial.
ICR Logo
ICR Chief Executive to Become Deputy Chairman of the Wellcome Trust

23/07/10

He will take up the position at the independent, global biomedical charity in October.
ICR Logo
Therapy Reduces Dangerous Side-effects

20/07/10

Children given a hormone growth factor alongside chemotherapy for the aggressive cancer neuroblastoma are less likely to suffer a potentially deadly side-effect.
ICR Logo
Breast Cancer Drugs May Treat Prostate Cancer

25/06/10

The way prostate cancer develops in men who have an altered ‘breast cancer gene’ is the same route by which breast cancer develops in women with the same mutation.

Make a donation today

A monthly gift can help support our research over several years, so it has the maximum possible benefit for people with cancer.
With GiftAid you'll also be able to add 25% at no extra cost to you

Please choose a donation amount.

With your generous support, we can continue making more discoveries, finding more cures, and saving more lives.
With GiftAid you'll also be able to add 25% at no extra cost to you

Please choose a donation amount.

Our research centres & divisions

Through our close partnerships with The Royal Marsden and other key UK institutions, we're leading a wide breadth of cancer research across eight divisions and more than 25 research centres and strategic initiatives.